Some real perspective, this isn't a to the moon lambo/mansion post. A lot of posts on here are clueless hype, this isn't, this is real.
The company ran a lot this week, some pullback is going to happen. Here is what we can say with a high level of confidence:
1) At this point, we know it isn't a pump & dump. Dr. Javitt and Dr. Ram would both be in jail if it was at some point. One is a well-respected doctor and CEO who has been involved in a lot of legit pharma dealings and the other is a successful investment banker. Neither of them would risk jail to commit severely fraudulent activities. Furthermore, when you read up on Dr. Javitt, he has government connections. Dr. Javitt is the clinical trials/science guy, Dr. Ram is the money man.
2) There is a floor here where buyers will absolutely come in based on clinical trials, it's not going back to 20 cents. At 50 cents, even though I own a lot at much lower, I buy more. Look out for bashing from the likes of an Adam Feurstein, use that as an opportunity to add to your position. I wouldn't personally take profits until $1.50.
3) There is a lot of float. GEM LLC is our enemy, not our friend. They loaned Relief tons of money prior to Covid at loan shark rates, they own endless shares. Those shares are free to them, of course they're going to sell a bunch of those shares with a cost basis of .01 and starting picking up profit. That's what all early investors do.
4) An inhaled FDA approved version of a Covid treatment in a perfect world would make this a $25 stock, that's the ceiling in a perfect world. Until we get there, with positive news, $3-$5B will be a fair price for a company showing promise in Covid treatment. Leaves plenty of room for upside in the coming month.
5) Look at who is on their clinical trials data monitoring committee: a congressman, a dean at Johns Hopkins, and a former white house appointed health director. This to me was one of the most bullish things I found when doing my DD earlier in the week.
6) If more data starts leaking out about successful treatment for critical patients, this will go up 300% that day.
7) This company should be a top 3 contender for therapeutics right now, don't let anyone scare you. On that alone, this company is still undervalued and should at a minimum double over the next month. Nothing is going to run like it did this week, that movement was based on the story behind this company, and at this point we know the story is real. Whether the drug works or not is still TBD, but based on what we know, the valuation is too low until at least $2B.
Stay strong, stay long. And at 50 cents, should it get there, you should consider adding to your position.